RVL Pharmaceuticals plc Quarterly Deferred Income Tax Liabilities, Net in USD from Q4 2017 to Q2 2023

Taxonomy & unit
us-gaap: USD
Description
Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.
Summary
RVL Pharmaceuticals plc quarterly Deferred Income Tax Liabilities, Net history and growth rate from Q4 2017 to Q2 2023.
  • RVL Pharmaceuticals plc Deferred Income Tax Liabilities, Net for the quarter ending June 30, 2023 was $25K, a 85.6% decline year-over-year.
Deferred Income Tax Liabilities, Net, Quarterly (USD)
Deferred Income Tax Liabilities, Net, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q2 2023 $25K -$149K -85.6% Jun 30, 2023 10-Q 2023-08-14
Q1 2023 $72K -$88K -55% Mar 31, 2023 10-Q 2023-05-11
Q4 2022 $61K -$90K -59.6% Dec 31, 2022 10-Q 2023-08-14
Q3 2022 $189K +$24K +14.5% Sep 30, 2022 10-Q 2022-11-10
Q2 2022 $174K -$437K -71.5% Jun 30, 2022 10-Q 2022-08-11
Q1 2022 $160K -$267K -62.5% Mar 31, 2022 10-Q 2022-05-12
Q4 2021 $151K -$194K -56.2% Dec 31, 2021 10-K 2023-03-20
Q3 2021 $165K -$361K -68.6% Sep 30, 2021 10-Q 2021-11-15
Q2 2021 $611K -$1.57M -72% Jun 30, 2021 10-Q 2021-08-16
Q1 2021 $427K -$1.9M -81.7% Mar 31, 2021 10-Q 2021-05-13
Q4 2020 $345K -$1.16M -77% Dec 31, 2020 10-K 2022-03-30
Q3 2020 $526K Sep 30, 2020 10-Q 2020-11-10
Q2 2020 $2.18M -$14.7M -87% Jun 30, 2020 10-Q 2020-08-11
Q1 2020 $2.33M -$24.9M -91.4% Mar 31, 2020 10-Q 2020-05-12
Q4 2019 $1.5M -$26.8M -94.7% Dec 31, 2019 8-K 2021-09-08
Q2 2019 $16.8M Jun 30, 2019 10-Q 2020-08-11
Q1 2019 $27.2M Mar 31, 2019 10-Q 2020-05-12
Q4 2018 $28.3M -$15.5M -35.4% Dec 31, 2018 10-K 2020-03-19
Q3 2018 $36.3M Sep 30, 2018 10-Q 2019-11-14
Q4 2017 $43.8M Dec 31, 2017 8-K 2019-12-20
* An asterisk sign (*) next to the value indicates that the value is likely invalid.